American Association for Cancer Research

Poster Session A

Poster Session A
Saturday, February 6
6:30 p.m.-8:00 p.m.

In alphabetical order, not board assignment order

  • A combination of intratumoral interferon-α gene transfer and syngeneic hematopoietic stem cell transplantation induces an effective antitumor immunity for solid cancers. Kenta Narumi, Atsushi Kondoh, Takahiro Ochiya, Teruhiko Yoshida, Kazunori Aoki. National Cancer Center Research Institute, Tokyo, Japan.
  • A fragment peptide originating from ANA activates an unfolded recombinant MMP-7. Aya Kojima, Motomi Konishi, Masatoshi Nishi, Toshifumi Akizawa. Setsunan University, Hirakata, Osaka, Japan.
  • A new method for detecting epistasis from genome-wide SNP data. Masaru Ushijima, Minoru Isomura, Yoshio Miki, Masaaki Matsuura. Japanese Foundation for Cancer Research, Tokyo, Japan.
  • A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to molecular target drugs in living chronic myeloid leukemia cells. Tatsuaki Mizutani, Takeshi Kondo, Darmanin Stephanie, Masumi Tsuda, Shinya Tanaka, Masahiro Asaka, Yusuke Ohba. Hokkaido University Graduate School of Medicine, Sapporo, Japan.
  • A simple and cost-effective somatic mutation detection method for clinical cancer treatment. Shiro Kitano1, Junko Nakamura1, Akio Yamane1, Masahiko Amano1, Mark J. Ratain2, Wanqing Liu2. 1Toppan Printing Co., Ltd., Kisarazu, Chiba, Japan, 2The University of Chicago, Chicago, IL.
  • An optimized Fisher liner classifier for detection of hepatocellular carcinoma. Yusuke Fujita1, Yoshihiko Hamamoto1, Norio Iizuka1, Toyoki Moribe2, Masaaki Oka1. 1Yamaguchi University, Ube, Japan, 2Roche Diagnostics K. K., Tokyo, Japan.
  • Antitumor effect for squamous cell carcinoma mediated by heat shock protein gp96. Yasunori Akutsu, Gulbostan Yusup, Aki Komatsu, Norimasa Ikeda, Masayuki Kano, Akihiro Usui, Haruhito Sakata, Yasuo Yoneyama, Yukimasa Miyazawa, Hisahiro Matsubara. Chiba University, Chiba, Japan.
  • Application of microcomputed tomography in pancreatic ductal carcinomas of Syrian hamsters. Tsukasa Kitahashi1, Michihiro Mutoh1, Masakatsu Tsurusaki2, Gen Iinuma2, Masahiro Suzuki3, Noriyuki Moriyama3, Mitsuyoshi Yoshimoto1, Keiji Wakabayashi1, Takashi Sugimura1, Toshio Imai1. 1National Cancer Center Research Institute, Tokyo, Japan, 2National Cancer Center Hospital, Tokyo, Japan, 3National Cancer Center, Tokyo, Japan.
  • Application of quantitative peptidomics for the identification of serum lung cancer biomarkers. Koji Ueda1, Taka-Aki Sato2, Yataro Daigo3, Nobuhisa Ishikawa4, Nobuoki Kohno4, Yusuke Nakamura3, Hidewaki Nakagawa1. 1Center of Genomic Medicine, RIKEN, Yokohama, Japan, 2Shimadzu Corporation, Kyoto, Japan, 3Institute of Medical Science, University of Tokyo, Tokyo, Japan, 4Hiroshima University, Hiroshima, Japan.
  • Approach for tumor diagnosis by inflow-time mapping of contrast ultrasonography. Kazuaki Sasaki1, Ayumu Kikuchi1, Masayuki Kobayashi1, Hideki Yoshikawa2, Takashi Azuma2, Minoru Shimoda1. 1Tokyo University of Agriculture and Technology, Tokyo, Japan, 2 Central Research Laboratory, Hitachi, Ltd., Tokyo, Japan.
  • Association of single nucleotide polymorphisms with Epirubicin-induced severe myelosuppression in Japanese patients. Yuvaraj Srinivasan1, Hitoshi Zembutsu2, Satoko Uno2, Yusuke Nakamura2. 1RIKEN, Center for Genomic Medicine, Tokyo, Minato-Ku, Japan, 2Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Minato-Ku, Japan.
  • Characterization of inflammation-associated systemic genotoxicity. Aya Melody Westbrook, Bo Wei, Katrin Hacke, Jonathan Braun, Robert H. Schiestl. University of California Los Angeles, Los Angeles, CA.
  • Chemokine BRAK/CXCL14 is a bifunctional tumor suppressor: Toward a tumor dormancy therapy without side effects. Ryu-Ichiro Hata, Kazuhito Izukuri, Kenji Suzuki, Nobuyuki Yajima, Shigeyuki Ozawa, Shin Ito, Eiro Kubota. Kanagawa Dental College, Yokosuka, Japan.
  • Clinicopathological features of patients 50 years old or younger with lung adenocarcinoma who harbor EML4-ALK fusion gene. Takuro Kometani, Kenji Sugio, Yoko Takeda, Kaname Nosaki, Hiroshi Okazaki, Fumihiko Hirai, Kaoru Ondo, Motoharu Hamatake, Takashi Seto, Yukito Ichinose. National Kyushu Cancer Center, Fukuoka, Japan.
  • Clinico-pathological significance of Glut-1 expression in non-small cell lung cancer. Takaoki Furukawa1, Yoshihiro Miyata1, Keizo Misumi1, Takuhiro Ikeda1, Yasuhiro Tsutani1, Morihito Okada1, Kei Kushitani1, Amatya V. Jeet1, Yukio Takeshima1, Kouki Inai1, Akihiro Sawamura2, Kazuma Shimura2. 1Hiroshima University, Hiroshima, Japan, 2Shimura Hospital, Hiroshima, Japan.
  • Detection of EGFR mutation by highly sensitive MALDI-TOF MS to predict EGFR-TKIs treatment response in non-small cell lung cancer patients. Kang-Yi Su1, Jin-Yuan Shih2, Hsi-Chun Kao1, Chu-Chun Hsu1, Chein-yu Lin1, Hsuan-Yu Chen1, Ker-Chau Li1, Sung-Liang Yu3, Chih-Hsin Yang4, Pan-Chyr Yang2. 1Institute of Statistical Sciences, Taipei, Taiwan, Departments of 2Internal Medicine and 4Oncology, National Taiwan University Hospital, Taipei, Taiwan, 3National Taiwan University, Taiwan, Taiwan.
  • Development of detection method for novel fusion gene using GeneChip Exon array. Yusaku Wada, Masaaki Matsuura, Minoru Sugawara, Masaru Ushijima, Satoshi Miyata, Koichi Nagasaki, Yoshio Miki, Tetsuo Noda. Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Development of high-throughput functional screening system for chemosensitivity-related genes using transfection cell array. Koichi Nagasaki, Takashi Shimoji, Yoshinori Ito, Takuji Iwase, Futoshi Akiyama, Masaaki Matsuura, Tetsuo Noda, Yoshio Miki. Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Development of specific quenched peptide substrate for membrane-type 1 matrix metalloproteinase (MT1-MMP). Rika Okihara, Aya Kojima, Ryuji Iemura, Motomi Konishi, Toshifumi Akizawa. Sestunan University, Hirakata, Osaka, Japan.
  • Dissecting mechanisms of metastasis using a mouse model of cancer. Rebecca Dodd, Jeffery Mito, Will Eward, Brian Brigman, Leslie Dodd, Sayan Mukherjee, David Kirsch. Duke University, Durham, NC.
  • Downregulation of SPARC protein expression is associated with poor prognosis in breast cancer. Maria A. Nagai1, Rene Gehard1, Suely Nonogaki2, José H. Fregnani3, Mário M. Mourão Netto2, Fernando A. Soares2. 1Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Fundação Antonio Prudente, São Paulo, Brazil, 3Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brazil.
  • Editing the pMHCI repertoire in the ER by tapasin and ERAAP. Takayuki Kanaseki1, Kristin Camfield1, Noriyuki Sato2, Nilabh Shastri1. 1University of California, Berkeley, Berkeley, CA, 2Sapporo Medical University, Sapporo, Hokkaido, Japan.
  • Effect of MUC1 plasmid DNA and BM-DCs vaccination in an experimental colon carcinogenesis in MUC1 transgenic mice. Retno Murwanti1, Daisuke Sugiura2, Kaori Denda-Nagai1, Mika Kamata-Sakurai1, Tatsuro Irimura1. 1Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan, 2Institute for Genome Research, University of Tokushima, Tokushima, Japan.
  • Entire-volume serial histological examination for detection of micrometastases in lymph nodes of colorectal cancers. Masaki Hata1, Junji Machi2, Jonathan Mamou3, Eugene T. Yanagihara4, Emi Saegusa-Beecroft2, Gregory K. Kobayashi4, Clifford C.M. Wong4, Conway Fung4, Ernest J. Feleppa3, Kazuhiro Sakamoto1. 1Juntendo University School of Medicine, Tokyo, Japan, Departments of 2Surgery and 4Pathology, University of Hawaii and Kuakini Medical Center, Honolulu, Hawaii, 3Riverside Research Institute, New York, NY.
  • Expression of Ret finger protein correlates with outcomes in endometrial cancer. Takuya Kato1, Hirohisa Tsukamoto1, Atsushi Enomoto2, Naoya Asai1, Yoshiki Murakumo1, Masahide Takahashi1. 1Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Nagoya University Institute for Advanced Research, Nagoya, Japan.
  • Galectin-3 polymorphisms and response of human breast and colon cancer cells to apoptotic stimuli. Suguru Ueno1, Yun Ji San2, Nachman Mazurek2, James C. Byrd2, Tatsuro Irimura1, Robert S. Bresalier2. 1University of Tokyo, Tokyo, Japan, 2UT M. D. Anderson Cancer Center, Houston, TX.
  • Genome-wide association of single nucleotide polymorphisms with gemcitabine-induced severe myelosuppression in Japanese patients. Satoko Uno1, Hitoshi Zembutsu1, Yasutoshi Kimura2, Shinomi Ina3, Michiaki Kubo4, Hiroki Yamaue3, Koichi Hirata2, Yusuke Nakamura1. 1Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan, 2Sapporo Medical University School of Medicine, Sapporo, Japan, 3Wakayama Medical University, School of Medicine, Wakayama, Japan, 4Center for Genomic Medicine, The Institute of Physical and Chemical Research, Yokohama, Japan.
  • Genome-wide association study to identify genetic marker for prediction of peripheral neuropathy of paclitaxel treatment. Minoru Isomura, Masaaki Matsuura, Tetsuo Noda. Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Identification and characterization of BCUP2 as a novel molecular target for breast cancer therapy. Jung-Won Kim1, Toyomasa Katagiri2, Chikako Fukukawa1, Yataro Daigo1, Toshihiko Nishidate1, Yusuke Nakamura1. 1Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2Institute of Genome Research, University of Tokushima, Tokushima, Japan.
  • Identification of a CpG island whose methylation is associated with lymph node metastasis of esophageal cancer. Ken Gyobu1, Satoshi Yamashita1, Tohru Niwa1, Hiroyasu Igaki2, Ryoji Kushima2, Harushi Osugi3, Shigeru Lee3, Satoru Kishida3, Keiichirou Morimura3, Toshikazu Ushijima1. 1National Cancer Center Research Institute, Tokyo, Japan, 2National Cancer Center Hospital, Tokyo, Japan, 3Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Identification of HLA-A*2402-restricted epitope peptide derived from ERas oncogene. Takehiko Iwauchi, Hiroaki Tanaka, Sadaaki Yamazoe, Ryouji Kaizaki, Masahiro Komoto, Ryousuke Amano, Eiji Noda, Naoshi Kubo, Kazuya Muguruma, Touru Inoue, Tsutomu Takashima, Masakazu Yashiro, Nobuya Yamada, Naoyoshi Onoda, Kiyoshi Maeda, Kiyoshi Maeda, Tetsuji Sawada, Bunzo Nakata, Masaichi Ohira, Tetsuro Ishikawa, Kosei Hirakawa. Osaka City University Graduate School of Medicine, Osaka, Japan.
  • Identification of precursor lesions of colorectal cancers with CpG island methylator phenotype by molecular-magnifying colonoscopy. Hiroo Yamano1, Eiichiro Yamamoto2, Seiko kamimae2, Hiromu Suzuki2, Kenjiro Yoshikawa1, Tomoaki Kimura1, Ryuusuke Kato1, Taku Harada1, Tamotsu Sugai3, Kohzoh Imai2, Yasuhisa Shinomura2, Minoru Toyota2. 1Akita Red Cross Hospital, Akita City, Japan, 2Sapporo Medical University, Sapporo City, Japan, 3Iwate Medical University, Morioka City, Japan.
  • IGF1R oncogenic pathway is activated in squamous cell lung cancer and correlated with high activity of cell proliferation. Tzu Hung Hsiao1, Pei Ying Lin1, Siao Han Wong1, Eric Y. Chuang2, Pan Chyr Yang3, Konan Peck1. 1Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, 2National Taiwan University, Taipei, Taiwan, 3National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.
  • Impact of oncolytic HSV in cancer immunotherapy. Masahiro Kagabu1, Toru Sugiyama1, George Coukos2, Andrea Facciabene2. 1Iwate Medical University, Morioka, Iwate, Japan, 2University of Pennsylvania, Philadelphia, PA.
  • Increased sensitivity to bortezomib as a result of CD40 signaling in multiple myeloma cells: Understanding the molecular mechanism. Che Kang Lim, Ei Leen Cheng, Charles A. Gullo. Singapore General Hospital, Singapore.
  • Inherent gene signature of stage II and III colorectal cancer leads an individual recurrence. Ichiro Takemasa1, Masakazu Miyake1, Masataka Ikeda1, Tsunekazu Mizushima1, Hirofumi Yamamoto1, Mitsugu Sekimoto1, Ryo Matoba2, Kenichi Matsubara2, Yuichiro Doki1, Masaki Mori1. 1Osaka University, Suita, Osaka, Japan, 2DNA Chip Research Inc, Yokohama, Kanagawa, Japan.
  • Isolation and characterization of artificial peptide probe for cancer cell. Tamiko Minamisawa, Kiyotaka Shiba. JFCR, Tokyo, Japan.
  • Long-term prognostic value of conventional peritoneal lavage cytology in patients undergoing curative colorectal cancer resection. Noura Shingo, Ohue Masayuki, Shingai Tatsushi, Yamada Terumasa, Miyashiro Isao, Ohigashi Hiroaki, Yano Masahiko, Ishikawa Osamu. Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
  • Low expression of insulin-like growth factor binding proteins predicts poor outcomes in ovarian cancer patients. Paul Haluska1, Sean C. Harrington1, Thahir Farzan1, Boris J. Winterhoff1, Karin M. Goodman1, Kimberly K. Kalli1, Konecny E. Gottfried2. 1Mayo Clinic, Rochester, MN, 2University of California Los Angeles, Los Angeles, CA.
  • M1 and M2 markers expression in macrophage from malignant pleural effusion of NSCLC patients. Chih-An Lin1, Aug Yuan2, Sung-Liang Yu1, Chao-Chi Ho2. 1National Taiwan University, Taipei, Taiwan, 2 National Taiwan University Hospital, Taipei, Taiwan.
  • Matrix metalloproteinase-2 expression in stromal tissues is a high-risk indicator for recurrence in stage II colon cancer. Tomohisa Furuhata, Yoshiko Tayama, Makoto Tayama, Kenji Okita, Toshihiko Nishidate, Makoto Meguro, Keisuke Harada, Takayuki Nobuoka, Yasutoshi Kimura, Toru Mizuguchi, Koichi Hirata. Sapporo Medical University, Sapporo, Japan.
  • MEK/ERK signaling regulates the GCIP expression to control metastasis in human non-small cell lung carcinoma cells. Kuan-Ting Lin1, Ming-Chung Chang2, Show-Mei Chuang1. 1National Chung-Hsing University, Taichung, Taiwan, 2National Cheng Kung University, Tainan, Taiwan.
  • Mitochondrial pharmacogenetic polymorphisms in high-dose 5-fluorouracil-associated hyperammonemic encephalopathy of cancer patients. Kun-Huei Yeh1, Hsun-Fang Fan2, Ying-Chun Shen3, Ann-Lii Cheng1. 1Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan, Departments of 2Oncology and 3Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
  • Molecular analysis for the differential diagnosis of cartilaginous tumors. Takashi Shimoji, Koiichi Nagasaki, Minoru Isomura, Yoshio Miki, Masaaki Matuura, Tetsuo Noda. Japanese Foundation for Cancer Research, Koutouku, Tokyo, Japan.
  • Molecular signature reveals lung adenocarcinoma and squamous-cell carcinoma are different diseases. Chien-Yu Lin1, Yo-Ru Chen1, Sung-Liang Yu2, Shin-Sheng Yuan1, Yi-Chiung Hsu1, Gee-Chen Chang3, Jeremy J.W. Chen4, Ker-Chau Li1, Hsuan-Yu Chen1, Pan-Chyr Yang5. 1Institute of Statistical Science, Academia Sinica, Taipei, Taiwan, 2National Taiwan University, Taipei, Taiwan, 3Taichung Veterans General Hospital, Tai-Chung, Taiwan, 4Institutes of Biomedical Sciences and Molecular Biology, National Chung Hsing University, Tai-Chung, Taiwan, 5National Taiwan University College of Medicine, Taipei, Taiwan.
  • Mucin 5AC (MUC5AC) is associated with adhesion and invasion of human pancreatic cancer cell. Sadaaki Yamazoe, Hiroaki Tanaka, Takehiko Iwauchi, Masahiro Komoto, Ryosuke Amano, Tetsuji Sawada, Eiji Noda, Naoshi Kubo, Kazuya Muguruma, Toru Inoue, Tsutomu Takashima, Nobuya Yamada, Masakazu Yashiro, Kiyoshi Maeda, Naoyoshi Onoda, Bunzo Nakata, Masaichi Ohira, Tetsuro Ishikawa, Kosei Hirakawa, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
  • Multicenter study regarding clinical usefulness of serum hTERTmRNA as biomarker of hepatocellular carcinoma. Norimasa Miura, Junichi Hasegawa, Goshi Shiota. Tottori University, Yonago, Japan.
  • Negative regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) signaling by murine protein serine/threonine kinase 38 (MPK38). Hyun-A Seong, Ravi Manoharan, Hyunjung Ha. Chungbuk National University, Cheongju, Republic of Korea.
  • Neural invasion induces cancer cachexia in murine model of pancreatic cancer. Shuichi Mitsunaga, Akira Imoto, Atsushi Ochiai. National Cancer Center Hospital East, Kashiwa, Japan.
  • Novel automated three-dimensional genome scanning based on the nuclear architecture of telomeres. Ludger R. Klewes1, Nir Katzir2, David Rourke3, Yuval Garini4, Sabine Mai1. 1MICB, Winnipeg, Manitoba, Canada, 2Applied Spectral Imaging, Midgal, Ha’Emek, Israel, 3Applied Spectral Imaging, Houston, TX, 4Bar Ilan University, Tel Aviv, Israel.
  • Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Sang Hwan Seo1, 3, Hyun Tak Jin2, 3, Sang Hoon Park1, Je In Youn1, Se Won Kim1, and Young-Chul Sung1. 1Division of Molecular and Life Science, Pohang University of Science and Technology, Pohang, Gyeongbuk, Republic of Korea, 2Genexine Inc., #205, Postech Biotech. Center, Gyeongbuk, Republic of Korea
  • Predicting response to gemcitabine and carboplatin (GC) chemotherapy for invasive bladder cancer through genome-wide expression profiling. Yoichiro Kato1, Hitoshi Zembutsu1, Ryo Takata2, Tomoaki Fujioka2, Yusuke Nakamura1. 1Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2Iwate Medical University, Morioka, Japan.
  • Predicting response to IL-2 and IFN-α combination therapy for renal cell carcinoma through genome-wide gene expression profiling. Osamu Mizumori1, Hitoshi Zembutsu1, Yoichiro Kato1, Taiji Tsukamoto2, Tomoaki Fujioka2, Yoshihiko Tomita2, Tadaichi Kitamura2, Seiichiro Ozono2, Tsuneharu Miki2, Seiji Naito2, Hideyuki Akaza3, Yusuke Nakamura1. 1The Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2IL-2 RCC Study Group, Tokyo, Japan, 3Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
  • Prediction of gemcitabine-induced toxicity and clinical course in patients with advanced pancreatic cancer. Junichi Matsubara1, Masaya Ono1, Hideki Ueno2, Takuji Okusaka2, Junji Furuse3, Koh Furuta2, Nahoko Kaniwa4, Junichi Sawada4, Nagahiro Saijo3, Tesshi Yamada1. 1National Cancer Center Research Institute, Tokyo, Japan, 2National Cancer Center Hospital, Tokyo, Japan, 3National Cancer Center Hospital East, Kashiwa, Japan, 4National Institute of Health Sciences, Tokyo, Japan.
  • Prediction of response to cancer chemotherapy by generalized additive model. Satoshi Miyata, Masaaki Matsuura. Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Requirement of hPygo2 in prostate cancer. Zhijian He, Kenneth Kao, Catherine Popadiuk. Memorial University, St. John's, Newfoundland and Labrador, Canada.
  • Robust multi-tissue gene panel for cancer detection. Joseph Irgon. Johnson & Johnson–Centocor, Inc., Rutgers University, New Brunswick, NJ, Institute for Advanced Study, Princeton, NJ.
  • Role of Rad51 downregulation and ERK1/2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small cell lung cancer cells. Yun-Wei Lin, Ying-Jhen Su, Min-Shao Tsai, Ya-Hsun Kuo, Yu-Fan Chiu. National Chiayi University, Chiayi, Taiwan.
  • Serum degradome markers for the detection of breast cancer. Annemieke van Winden1, Irene van den Broek2, Marie-Christine Gast3, Judith Engwegen3, Rolf Sparidans2, Eric van Dulken3, Annekatrien Depla3, Annemieke Cats4, Jan Schellens4, Petra Peeters1, Jos Beijnen3, Carla van Gils1. 1Julius Center, University Medical Center Utrecht, Utrecht, The Netherlands, 2Faculty of Science, University Utrecht, Utrecht, The Netherlands, 3Slotervaart Hospital, Amsterdam, The Netherlands, 4Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Signatures for the recurrence of hepatocellular carcinoma determined by proteomics of nontumorous liver tissues. Mariko Esumi1, Hiromi Yamaguchi1, Kazumichi Kuroda1, Yasuaki Munekata1, Masahiko Sugitani1, Fumi Fuchinoue1, Kiyoshi Hasegawa2, Takao Mamiya1, Tadatoshi Takayama1, Norihiro Kokudo2, Hiroki Nagase1, Masako Mitsumata1. 1Nihon University School of Medicine, Tokyo, Japan, 2University of Tokyo, Tokyo, Japan.
  • Significant effect of polymorphisms in CYP2D6 and DT-1 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. Hitoshi Zembutsu1, Kazuma Kiyotani2, Taisei Mushiroda2, Chiyo K. Imamura3, Naoya Hosono2, Tatsuhiko Tsunoda2, Michiaki Kubo2, Yusuke Tanigawara3, Flockhart A. David4, Desta Zeruesenay4, Todd C. Skaar4, Fuminori Aki5, Hirata Koichi6, Yuichi Takatsuka7, Minoru Okazaki8, Shozo Ohsumi9, Takashi Yamakawa10, Mitsunori Sasa11, Yusuke Nakamura1. 1I.M.S. University of Tokyo, Tokyo, Japan, 2C.G.M. Riken, Yokohama, Japan, 3Keio University, Tokyo, Japan, 4Indiana University, Indianapolis, IN, 5Itoh-geka, Kochi, Japan, 6Sapporo Medical University, Sapporo, Japan, 7Kansai Rousai Hospital, Amagasaki, Japan, 8Sapporo Nyusen Geka, Sapporo, Japan, 9Shikoku Cancer Center, Ehime, Japan, 10Yamakawa Clinic, Kochi, Japan, 11Tokushima Bre. Clinic, Tokushima, Japan.
  • Systemic delivery of myxoma virus to brain tumors via adipose-derived stem cells. Gustavo J. Dreher1, Fernanda Dreher1, Dongqin Zhu1, Wenhong Chen1, Michael Callahan1, Grant McFadden2, Hannah Caldas1. 1Wake Forest University School of Medicine, Winston-Salem, NC, 2University of Florida, Gainesville, FL.
  • Systemic delivery of siRNA specific to tumor mediated by atelocollagen: Combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Ping Mu, Kenji Kadomatsu, Yoshifumi Takei. Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Targeting liposome mediated by a novel peptide ligand increases therapeutic index of drug against breast cancer. Han-Chung Wu, Chien-Yu Chiu, Shin-Long Yan, De-Kuan Chang, Wei-Chuan Lin. Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
  • The expression of protein kinase C α and transcription factors in human breast cancer cells. Yue Chia-Herng1, Hsu Li-Sung2, Tzang Bor-Show2, Shiu Jiuan-Jen3, Liu Jer-Yuh4, Hwang Jin-Ming5. 1Tungs’ Taichung MetroHarbor Hospital, Taichung County, Taiwan, 2Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan, 3Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan, 4Graduate Institution of Cancer Biology, China Medical University, Taichung, Taiwan, 5School of Applied Chemistry, Chung-Shan Medical University, Taichung, Taiwan.
  • The ribonucleotide reductase subunit M1 expression assessed by quantitative double-fluorescence immunohistochemistry is a useful chemoresistant marker of gemcitabine in biliary tract carcinoma. Keita Kai, Naohiko Kohya, Jun Nakamura, Kazuma Ohtaka, Kazuyoshi Hashiguchi, Hiraki Masatsugu, Yoshihiko Kitajima, Osamu Tokunaga, Hirokazu Noshiro, Kohji Miyazaki. Saga University, Saga, Japan.
  • The role of long-form collapsin response mediator protein-1 (LCRMP-1) in cancer angiogenesis. Szu-Hua Pan1, Pei-Fang Hung2, Yih-Leong Chang1, Chen-Tu Wu1, Cheng-Chi Chang1, Tse-Ming Hong3, Pan-Chyr Yang1. 1National Taiwan University, Taipei, Taiwan, 2National Defense Medical Center, Taipei, Taiwan, 3National Cheng Kung University, Tainan, Taiwan.
  • The role of peroxisome proliferator-activated receptor gamma (PPAR?) in growth inhibition and apoptosis of human multiple myeloma and B lymphoma cells. Tatiana M. Garcia-Bates, Steven H. Bernstein, Richard P. Phipps. University of Rochester School of Medicine and Dentistry, Rochester, NY.
  • Transactivation of PARPBP (PARP1-binding protein) in pancreatic cancer enhances PARP1 (poly ADP-ribose polymerase 1) activity and promotes cell growth. Lianhua Piao1, Hidewaki Nakagawa2, Kotoe Kashiwaya3, Su-youn Chung1, Koji Ueda2, Hidetoshi Eguchi4, Hiroaki Ohigashi4, Yataro Daigo1, Yusuke Nakamura1. 1Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2Center of Genomic Medicine, RIKEN, Tokyo, Japan, 3Institute of Medicine, Sapporo Medical University, Sapporo, Japan, 4Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
  • Tumor initiation and progression of thyroid cancer impacts on telomeres as shown by three-dimensional imaging. Landon Wark1, Sabine Hombach-Klonisch2, Sheue-Yann Cheng3, Sabine Mai1, Thomas Klonisch2. 1The Genomic Centre for Cancer Research and Diagnosis, Winnipeg, Manitoba, Canada, 2Human Anatomy & Cell Science, University of Manitoba, Winnipeg, Manitoba, Canada, 3Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD.
  • UHRF1 as a possible biomarker for diagnosis and the prognosis of bladder cancer. Motoko Unoki1, Ryuji Hamamoto2, Yusuke Nakamura2. 1RIKEN, Tokyo, Japan, 2Tokyo University, Tokyo, Japan.
  • Upregulation of IGF2 (insulin-like growth factor 2) is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma. Takenori Ogawa1, Kazumi Ogawa1, Kiyoto Shiga1, Toru Furukawa1, Sho Hashimoto2, Toshimitsu Kobayashi1, Akira Horii1. 1Tohoku University School of Medicine, Sendai, Japan, 2Sendai National Hospital, Sendai, Japan.
  • VEGF165b, a splice variant of VEGF-A, is a prognostic factor in colorectal cancer. Toshihiko Nishidate, Tomohisa Furuhata, Makoto Tayama, Yoshiko Tayama, Kenji Okita, Yasutoshi Kimura, Toru Mizuguchi, Koichi Hirata. Sapporo Medical University, Sapporo, Japan.
  • VeraTag p95 HER-2/neu primary tumor level and outcome in trastuzumab-treated metastatic breast cancer patients. Kim Leitzel1, Jeff Sperinde2, Xueguang Jin2, Jayee Banerjee2, Weidong Huang2, Elicia Penuel2, Jodi Weidler2, Suhail M. Ali3, Eva-Maria Fuchs4, Christian F. Singer4, Wolfgang Köstler4, Michael Bates2, Gordon Parry2, John Winslow2, Allan Lipton1. 1Penn State/Hershey Medical Center, Hershey, PA, 2Monogram Biosciences, South San Francisco, CA, 3Lebanon VA Medical Center, Lebanon, PA, 4Medical University of Vienna, Vienna, Austria.
Poster Session A Poster Session B Poster Session C Poster Session D